About Insulet
Insulet is a publicly listed company based in Boston (United States) founded in 2000. Wearable insulin infusion systems are developed for diabetes patients. It operates in the Healthcare and Technology sectors. Insulet has raised $120.4 million across 8 funding rounds from investors including TIAA, Orbimed and FirstMark. The company has 3,900 employees. Its chief executive, as recorded, is Duane DeSisto. Its website insulet.com draws about 132 thousand monthly visits. Insulet offers products and services including Omnipod. Its focus areas include Life Sciences, Drug Delivery, Patches and Microneedle Patch. Its legal entity is Insulet Corporation. Its competitors include Tandem Diabetes, Xeris Pharmaceuticals and Lyra Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Insulet was founded in 2000 and is headquartered in Boston, United States. Operations focus on the medical device sector, where insulin infusion systems for insulin-dependent diabetes are developed, manufactured, and marketed. A key product includes a disposable infusion device with automated cannula insertion, paired with a handheld wireless diabetes manager. This setup supports diabetes management through integrated monitoring and delivery features.
- Headquarters Boston, United States
- Employees 3,900
- Stage Public
- SectorsHealthcareTechnology
- Phone•••• ••••
- Website insulet.com
- Social LinkedIn
- Legal Name Insulet Corporation
- Annual Revenue$2.71 B (USD)30.73as on Dec 31, 2025
- Net Profit$247.1 M (USD)-40.93as on Dec 31, 2025
- EBITDA$586.9 M (USD)43.88as on Dec 31, 2025
- Total Equity Funding$120.4M (USD)
in 8 rounds
- Latest Funding Round$201M (USD), Post-IPO
Jun 2014
- InvestorsTIAA
& 12 more
- Employee Count3,900
Products & Services of Insulet
Insulet offers a comprehensive portfolio of products and services, including Omnipod.
Tubeless wearable device for continuous insulin delivery to diabetes patients.
Funding Insights of Insulet
Insulet has successfully raised a total of $120.4M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $201 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.4M
- Total Rounds 8
- Last Round Post-IPO — $201M
- First Round $1M
(Jun 2000)
- Investors Count 13
All 8 funding rounds of Insulet with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | $201M | Post-IPO | – | – | – |
| Mar 2009 | $60M | Debt – Venture | – | – | |
| Jan 2007 | $899,995 | Series E | – | – | – |
| Feb 2006 | $50M | Series E | – | – | |
| Mar 2004 | $35.5M | Series D | – | – | |
| Oct 2002 | $22M | Series C | – | – | |
| Aug 2001 | $11M | Series A | – | – | |
| Jun 2000 | $1M | Seed | – | – |
13 investors in total: 13 institutional.
Investors in Insulet
Insulet has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include TIAA, Orbimed and FirstMark.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Early-stage venture capital is invested in tech startups across sectors. | 1987 | firstmark.com | New York, United States | |
VC firm investing in the US | prismventure.com | Westwood, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Life sciences sector focused VC firm funding companies in the US | medven.com | Emeryville, United States | ||
Growth stage VC fund investing in the US, Europe and Canada | oakwoodmedical.com | St. Louis, United States | ||
| federatedinvestors.com |
Investor details for Insulet
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Insulet
856 people are tracked at Insulet (201 in leadership, 8 in board & advisors, 647 in team); the tracked headcount is 3,900.
| Name | Role | Group |
|---|---|---|
Duane DeSisto | Ex-CEO | Leadership |
Peter Majeski | Director | Leadership |
Masuma Imran | Director, Software Test Engineering | Leadership |
Kieran Whelan | Director, Component Capacity | Leadership |
Zoltan Szantai | European HR Business Partner | Leadership |
Larry Matteson | Director Of Product Management | Leadership |
Chetan Dhillon | Sr Director, Software Engineering | Leadership |
Efdal Elferri | Sr. Director, Agile Delivery, Medical Device R&d And Cloud | Leadership |
Leonardo Hermosillo | Head Of Global Finance Operations | Insulet Capability Center Guadalajara MD | Leadership |
Rahul Sarvadevabhatla | Sr. Director, Lifecycle Engineering | Leadership |
Peter Gowac Jr. | Senior Director, US Operations | Leadership |
Aarthy Balakrishnan | Director, Software Engineering | Leadership |
Christina Yoo | Human Resources Business Partner | Leadership |
Steven Parrella | Director, IT Global Information Technology Partnership | Leadership |
Tori Rohlsson | Director, Talent Acquisition | Leadership |
Jay Mansavage | Director Talent Acquisition | Leadership |
Tj Niglio | Group Vice President, Chief Procurement Officer | Leadership |
Tom Andersen | Chief IP Counsel, VP | Leadership |
Trang Ly | SVP & Medical Director | Leadership |
Laura Miles | Global Head Of Talent Acquisition Operations | Leadership |
836 more people are available in the full profile.
Complete people profiles for Insulet
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Insulet
Insulet is a publicly listed company on the NASDAQ with ticker symbol PODD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 May 2007
- Listed onNASDAQ: PODD
- Listed entityInsulet Corporation
- Exchange sectorHealth technology
- ISINUS45784P1012
- Share price$138.13 (-1.2% on the day) · 2026-10-13
- Market capitalisation$9.58B
- Price to earnings27.4
- EPS (diluted, trailing year)$5.04
- Volume (last session)1,347,395
Financials of Insulet
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.71B | $247.1M | $586.9M |
| 2024 | $2.07B | $418.3M | $407.9M |
| 2023 | $1.70B | $206.3M | $292.8M |
| 2022 | $1.31B | $4.6M | $100.8M |
| 2021 | $1.10B | $16.8M | $183.4M |
Detailed financial statements for Insulet
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Insulet
4 dated milestones of Insulet across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Insulet is founded.
- Funding First funding round of $1.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $201.0M.
Competitors of Insulet
Insulet has 3 listed competitors in our database, 3 of them funded. They include Tandem Diabetes, Xeris Pharmaceuticals and Lyra Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tandemdiabetes.com | 2008 | San Diego, United States | $100.73M | 1,922 | Developer of devices for continuous glucose monitoring and manual insulin delivery | |
| xerispharma.com | 2005 | Chicago, United States | $110.43M | 294 | Liquid-stable injectables are developed for peptide and protein drug delivery. | |
| lyratherapeutics.com | 2005 | Watertown, United States | $127.61M | 75 | Small molecule therapeutics for ENT diseases are developed. |
Detailed competitors of Insulet
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Insulet
The website of Insulet (insulet.com) receives about 132.4K visits a month.
- Monthly visits132.4K
▲ 16.6% vs previous month
Websites whose visitors overlap most with Insulet. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| parexel.com | 100% | 220.8K | #203,256 | View details | |
| trizetto.com | 100% | 9K | #2,239,071 | View details | |
ssspr.com | ssspr.com | 100% | #731,855 | – | |
| bd.com | 100% | 1.2M | #57,463 | View details | |
| quidel.com | 100% | #5,902,749 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Insulet
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diabetes
3 companies that operate in the same segment as Insulet (Diabetes) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Insulet
Complete news archive for Insulet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Insulet
Insulet was founded in 2000.
Insulet is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Duane DeSisto is the CEO of Insulet, as recorded in our data.
Insulet is a funded company, having raised a total of $120.4M across 8 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Jun 2000.
Insulet has 3,900 employees.
Annual revenue of Insulet is $2.71B as on Dec 31, 2025.
Insulet was founded in 2000 and is headquartered in Boston, United States. Operations focus on the medical device sector, where insulin infusion systems for insulin-dependent diabetes are developed, manufactured, and marketed. A key product includes a disposable infusion device with automated cannula insertion, paired with a handheld wireless diabetes manager. This setup supports diabetes management through integrated monitoring and delivery features.
Insulet's top competitors include Tandem Diabetes, Lyra Therapeutics and Xeris Pharmaceuticals.
Insulet offers Omnipod.
Yes, Insulet is publicly traded on NASDAQ under the ticker symbol PODD.
Insulet has 13 investors. Key investors include TIAA, Orbimed, FirstMark, Piper Jaffray, and Deerfield.
Insulet operates through Insulet Corporation.